[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nf1-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nf1-mutation":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,76,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":50,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100495785","phase-2-mt2021-08t-cell-receptor-alphabeta-depletion-pbsc-transplantation-for-heme-malignancies-100495785",false,"NCT05735717","MT2021-08T Cell Receptor Alpha\u002FBeta Depletion PBSC Transplantation for Heme Malignancies","Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha\u002FBeta Depletion (A\u002FB TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies","Inclusion Criteria:\n\n* Histological confirmation of hematological malignancies\n* Acute leukemias\n* Acute Myeloid Leukemia (AML) and related precursor neoplasms\n* Favorable risk AML is defined as having one of the following:\n* Acute lymphoblastic leukemia (ALL)\u002Flymphoma\n* Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.\n* Age 60 years of age or younger at the time of consent\n* Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Active uncontrolled infection within 1 week of starting preparative therapy\n* Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR.\n* Any prior autologous or allogeneic transplant\n* CML blast crisis\n* Active central nervous system malignancy","ALL","60 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a phase II, open-label, prospective study of T cell receptor alpha\u002Fbeta depletion (TCR α\u002Fβ TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety\u002Ffeasibility study of the investigational procedure\u002Fproduct.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49],"Hematologic Malignancy","Acute Leukemia","Remission","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","AML","TP53","Intrachromosomal Amplification of Chromosome 21","Cytogenetic Abnormality","CNS Leukemia","Minimal Residual Disease","Myelodysplasia","Juvenile Myelomonocytic Leukemia","Somatic Mutation","PTPN11 Gene Mutation","N-RAS Gene Amplification","Neurofibromatosis 1","NF1 Mutation","CBL Gene Mutation","Monosomy 7","Chromosome Abnormality","Fetal Hemoglobin","Lymphoblastic Lymphoma","High Grade Non-Hodgkin's Lymphoma, Adult",[51,52,53,54,55,56,57,58,59,60,61,62],"Bu","Flu","G-CSF","GFSR","aGVHD","HCT","MAC","Mel","PBSCT","PTLD","RECIST","TCR","RECRUITING","2026-03-31",{"date":66,"type":67},"2026-04-06","ACTUAL",{"date":69,"type":67},"2023-05-11",{"date":71,"type":20},"2030-11-30",{"name":73,"class":74},"Masonic Cancer Center, University of Minnesota","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100589988","phase-1-pas-004-in-adults-who-have-neurofibromatosis-type-1-with-plexiform-neurofibromas-100589988","NCT06961565","PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas","A Phase 1\u002F1b Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a MAPK\u002FERK Kinase 1\u002F2 (MEK 1\u002F2) Inhibitor, in Adult Participants With Neurofibromatosis Type 1 (NF1) With Symptomatic and Inoperable, Incompletely Resected, or Recurrent Plexiform Neurofibromas","Inclusion Criteria:\n\n1. Participant is capable of providing informed consent, which includes compliance with the requirements, prohibitions and restrictions listed in the informed consent form.\n2. Participant has been informed both verbally and in writing about the objectives of the clinical study, the methods, the anticipated benefits, the potential risks, and the discomfort to which they may be exposed and has given written consent to participation in the study prior to study start and any study-related procedure.\n3. Participant must be at least 18 years of age at the signing of the informed consent form (ICF).\n4. Participant must be able to swallow oral medication.\n5. Performance status: Participant must have a Karnofsky performance level of ≥70%. Note: Participants who are wheelchair bound because of paralysis secondary to a PN should be considered ambulatory when they are in the wheelchair. Similarly, participants with limited mobility secondary to the need for mechanical support (such as an airway PN requiring tracheostomy or CPAP) will also be considered ambulatory for the purposes of this study.\n6. Participant has been diagnosed with NF1 based upon the following diagnostic criteria:\n\n   a. Clinical and imaging confirmation meeting at least two of the following NF1 diagnostic criteria in accordance with the clinical NIH consensus criteria: i. ≥ Six cafe-au-lait macules \\> 1.5 cm in maximum diameter ii. Axillary and\u002For inguinal freckling iii. ≥ Two neurofibromas of any type, or ≥ 1 plexiform neurofibroma; iv. An optic pathway glioma (prior diagnosis without concurrent disease is acceptable) v. ≥ Five Lisch nodules (iris hamartomas). Note: must be confirmed on slit lamp exam by an ophthalmologist if this is one of only two criteria met for diagnosis vi. A distinctive bony lesion such as dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex vii. Biologic parent with confirmed diagnosis of NF1 viii. Genetic testing demonstrating a pathogenic NF1 germline mutation per CLIA-certified laboratory (or equivalent) testing.\n\n1\\. Note: NF1 germline pathologic mutation positive must either be confirmed by the central laboratory or have documentation of NF1 mutation issued by a CLIA-certified laboratory (or equivalent). 2. No concern by the Investigator that an NF1 mimic, including but not limited to Noonan Syndrome, Legius Syndrome, or schwannomatosis could potentially serve as a more likely diagnosis\n\n7\\. Participants satisfying the NF1 diagnostic criteria outlined in Inclusion Criterion #6 must also meet one of the following criteria:\n\na. Participant has at least one symptomatic PN (\"Target PN\") measuring at least 3 cm on maximal cross-sectional (axial) diameter that is judged by the Investigator to be likely responsible for participant symptoms (such as pain, deformity, or neurologic disability), and unable to be completely resected without causing substantial damage\u002Ffunctional deficit, or unsuitable for surgery with high surgical risks.\n\nb. Participant has an incompletely resected symptomatic PN with a postoperative residual of at least 15% of the primary lesion and measuring at least 3 cm on cross-sectional (axial) diameter.\n\nc. Participant has a recurrent symptomatic PN measuring at least 3 cm in maximal cross-sectional (axial) dimension after prior resection.\n\n8\\. Participants should have a minimum of seven measurable CN measuring 6-15 mm (if participants satisfy Inclusion Criterion #6 and have no CN or less than 7 CN they still might be considered for the study as judged by the Investigator and Sponsor).\n\n1. Measurable is defined as: 1. non-pedunculated (no stalk) 2. surrounded by visually uninvolved skin and not in physical contact with another CN, 3. measuring between 6 and 15 mm in the longest diameter and exophytic on visual exam (not macular).\n2. At least seven CN should be located on the trunk, neck, and\u002For limbs measuring between 6 and 15 mm in maximal diameter, and \"measurable\" as per the definition listed above.\n3. Participants with CN meeting the above criteria will undergo optional resections of at least two CN that meet eligibility criteria. If participant is willing to accept additional CN resections, this is permitted for up to four additional lesions after completion of six PAS-004 treatment cycles or after early withdrawal as long as there are sufficient lesions to allow efficacy assessment.\n\n   9\\. Participant must be able and willing to undergo serial MRI scans as outlined in the study protocol.\n\n   Note: Anxiolytic medication or pain medication as deemed clinically appropriate by the Investigator is permissible for the purposes of managing anxiety, claustrophobia, and pain during MRI.\n\n   10\\. Participant must be able and willing to undergo serial 2-D and where available 3-D photography as well as caliper measurements as outlined in the study protocol.\n\n   11\\. Participant must have an international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.\n\n   12\\. Participant must have adequate organ and bone marrow function at screening as indicated by the following laboratory value ranges:\n\na. Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL b. Hemoglobin ≥ 90 g\u002FdL c. Platelets ≥ 100 × 109\u002FL d. Serum total bilirubin ≤ 1.5 × ULN for age (≤ 3.0 × ULN in participants with Gilbert's syndrome) e. Serum total bilirubin ≤ 1.5 × ULN (Serum total bilirubin can be ≤ 3.0 × ULN if participants have hemolysis or congenital hemolytic diseases) f. Aspartate aminotransferase (AST) ≤ 2.0 × ULN g. Alanine aminotransferase (ALT) ≤ 2.0 × ULN h. Albumin ≥ 3 g\u002FdL i. Creatinine clearance ≥ 60 mL\u002Fmin\n\n13\\. Participant must either agree to maintain abstinence (no heterosexual intercourse), or to use one highly effective form of contraception during study treatment and for at least 90 days after the last dose of investigational product (IP). Sperm-producing participants must agree not to donate sperm while receiving IP and for at least 90 days after the last dose of IP.\n\nExclusion Criteria:\n\n1. Participant has participated in another interventional clinical study within 28 days of starting PAS-004.\n2. Participant has received chemotherapy for any indication within 90 days of starting PAS-004.\n3. Participant has ongoing side effects from prior chemotherapy that are worse than mild (except alopecia). (\"Mild\" is defined as Asymptomatic or mild symptoms, clinical or diagnostic observations only, or intervention not indicated.)\n4. Participant has received treatment with any PN-directed drug or biologic therapy within 14 days of starting PAS-004.\n5. Participant has received treatment with a strong CYP3A4 inhibitor or inducer, or moderate inducers for CYP2C8 and CYP2C9 within 14 days of starting PAS-004, or any drug considered a major substrate of the enzymes above with a narrow therapeutic index except for topical skin use, as judged by the Investigator and Sponsor.\n6. Participant has received growth factors to increase the number or function of platelets or white blood cells within 7 days of starting PAS-004.\n7. Participant has received radiotherapy, major surgery, or immunotherapy within 28 days of starting PAS-004.\n8. Participant has malignant tumors associated with NF1 requiring chemotherapy, radiotherapy, or surgery, such as intermediate- to high-grade gliomas or malignant peripheral nerve sheath tumors.\n9. Participant has a current malignancy (excluding cured non-melanomatous skin cancer, breast carcinoma in situ, or cervical cancer in situ) or has history of malignancy requiring active treatment within the past 5 years (excluding cured non-melanomatous skin cancer, breast carcinoma in situ, and cervical cancer in situ). Other tissue-limited low stage cancers can be assessed by the Sponsor for possible inclusion on a per-participant basis.\n10. Participant has uncontrolled hypertension defined as blood pressures \\>150\u002F90 mmHg on repeat examinations despite maximal medical management.\n\n    Note: Participants with controlled hypertension with anti-hypertension therapy are permitted, as judged by the Investigator and Sponsor.\n11. Participant has active dysphagia, digestive system disease, malabsorption syndrome, or other conditions that might affect the absorption of PAS-004.\n12. Participant has previous or current retinal vein occlusion (RVO), retinal pigment epithelial detachments (RPED), clinically active glaucoma, or other significant abnormality in screening ophthalmic examination.\n13. Participant has interstitial pneumonia, NF1-related pulmonary disease, including existing clinically significant radiation pneumonitis.\n14. Participant has impaired cardiac function or cardiac disease as indicated by:\n\n    1. Average QTc interval \\> 480 ms calculated using the Fridericia's QT interval correction formula.\n    2. Grade ≥ 3 congestive heart failure per New York Heart Association (NYHA) guidelines.\n    3. Clinically significant arrhythmias, including but not limited to, complete left bundle branch conduction abnormalities and 2nd degree atrioventricular block.\n    4. Known concurrent clinically significant coronary artery disease, cardiomyopathy, or severe valvular disease.\n    5. Echocardiogram or multi-gated acquisition (MUGA) scan performed during the screening showing impaired left ventricular ejection fraction (LVEF) \\\u003C 45%.\n15. Participant has taken a QTc-prolonging medication within seven days of IP initiation or longer if the half-life of the QTc prolonging medication is such that the drug is not cleared from the body within 7 days (5 half-lives) of IP initiation.\n16. Participant has an uncontrolled bacterial, fungal, or viral infections, including active hepatitis B (hepatitis B virus surface antigen positive and hepatitis B virus DNA \\> 1000 IU\u002Fml or meeting the study site's diagnostic criteria for active hepatitis B infection), hepatitis C (hepatitis C virus RNA positive), or human immunodeficiency virus (HIV) infection with detectable viral load.\n17. Any clinically significant active or known history of liver disease or known hepatobiliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n18. Participant has a known hypersensitivity to PAS-004, its excipients, or another MEK 1\u002F2 inhibitor.\n19. Participant is pregnant or lactating.\n20. Participant has a clinically significant condition that, in the opinion of the investigator, would preclude study participation or compliance with safety requirements.\n21. Participant is unable to attend in-person clinic visits per clinical site guidelines and restrictions.","18 Years",{"count":85,"type":20},56,[87],"PHASE1","The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1). The main questions it aims to answer are:\n\n* How well participants are able tolerate different doses of PAS-004, and\n* What side effects PAS-004 might have.\n\nThis study will have two parts, Part A and Part B. The main goal of Part A of this study is to learn more about how participants tolerate different doses of PAS-004, and what side effects PAS-004 might have. What we learn from Part A of the study will help decide what doses of the study drug (PAS-004) should be used in Part B of the study, and if it is safe.\n\nIn Part B, two different doses from Part A will be tested. The main goal of this part of the study is to keep studying any side effects of PAS-004 at those two dose levels, and to learn more about if the doses picked for this part of the study might have an effect on plexiform neurofibromas.\n\nParticipants in Part A of the study who were taking doses selected for Part B may be able to continue on to Part B and keep taking the same dose of PAS-004 for 6 more months.\n\nStudy participants in both parts will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety, including blood draws and MRIs. Everyone participating in the study will take PAS-004 by mouth once a day during the study, in 28-day cycles. Participants will be asked to keep a diary to record their daily dose of study drug.\n\nParticipants will continue on daily PAS-004 for up to 6 months, or until:\n\n* They decide to withdraw from the study, or\n* They experience unacceptable side effects, or\n* Their disease progresses, or another illness interferes with taking the study drug, or\n* The sponsor selects a dose level to study further in the next part of the study, or\n* The sponsor stops the study.",[43,90,91,92,93],"Neurofibroma Plexiform","Neurofibroma, Plexiform","Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)","Neurofibromatosis Type 1 (NF1)",[95,96,97,98,99],"NF1","neurofibromatosis","plexiform neurofibroma","cutaneous neurofibroma","neurofibromatosis type 1","2025-11-26",{"date":102,"type":67},"2025-12-04",{"date":104,"type":67},"2025-05-30",{"date":106,"type":20},"2027-12",{"name":108,"class":109},"Pasithea Therapeutics Corp.","INDUSTRY",5,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100539130","phase-1-pas-004-in-patients-with-advanced-solid-tumors-100539130","NCT06299839","PAS-004 in Patients With Advanced Solid Tumors","A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1\u002F2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF\u002FMEK Inhibition","Inclusion Criteria:\n\n1. Capable of giving signed informed consent which includes compliance with the requirements, prohibitions and restrictions listed in the informed consent form (ICF).\n2. Patient has been informed both verbally and in writing about the objectives of the clinical study, the methods, the anticipated benefits, the potential risks, and the discomfort to which they may be exposed and has given written consent to participation in the study prior to study start and any study-related procedure.\n3. Patient must be at least 18 years of age at the time of signing the ICF.\n4. Patient must be able to swallow oral medication.\n5. Patient with histologically or cytologically diagnosed mitogen-activated protein kinase (MAPK) pathway driven advanced solid tumors with all of the following characteristics:\n\n   1. Tumor cannot be surgically resected\n   2. Patient has failed or is ineligible for standard of care therapy\n   3. Patient has no available treatment options with known clinical benefit\n   4. Documented evidence of rat sarcoma virus (RAS), neurofibromatosis type I (NF1), and\u002For rapidly accelerated fibrosarcoma (RAF) mutations. Patients with RAF mutations must have previously failed v-Raf murine sarcoma viral oncogene homolog B (BRAF) \u002F MEK inhibition.\n6. Prior to enrollment, patients without an existing prior genetic test result or adequate tumor tissue sample must agree to provide tumor tissue via biopsy (paraffin section or fresh tissue specimens) that will be sent for analysis to confirm eligibility.\n7. Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix B).\n8. Patient must have an estimated life expectancy of at least 12 weeks in the opinion of the Investigator at the time of informed consent.\n9. Patient must have adequate organ function at screening as indicated by the following laboratory value ranges:\n\n   1. Serum total bilirubin ≤ 1.5 × upper limit normal (ULN) (Serum total bilirubin can be ≤ 3.0 × ULN if patients have hemolysis or congenital hemolytic diseases)\n   2. Aspartate aminotransferase (AST) ≤ 2.5 × ULN or 5 × ULN for patient with liver metastases\n   3. Alanine aminotransferase (ALT) ≤ 2.5 × ULN or 5 × ULN for patient with liver metastases\n   4. Albumin ≥2 mg\u002FdL\n   5. Creatinine clearance ≥ 45 mL\u002Fmin (as calculated per Cockcroft-Gault)\n   6. Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL\n   7. Platelets ≥ 100×109\u002FL\n   8. Hemoglobin ≥ 90 g\u002FL (Note: Criteria must be met without a transfusion within 2 weeks of obtaining the sample)\n10. Patient must agree to maintain abstinence (no heterosexual intercourse) or use a highly effective form of contraception during study treatment and for at least 90 days after the last dose of IP. Male patients must agree not to donate sperm while receiving IP and for at least 90 days after the last dose of IP.\n\nExclusion Criteria:\n\n1. Participation in another therapeutic clinical trial within 3 weeks of enrollment.\n2. Having received chemotherapy, radiotherapy, major surgery, targeted therapy, immunotherapy, or other antitumor treatment within 21 days of enrollment or five half-lives of the administered therapy, whichever occurs first.\n3. Known or active central nervous system metastases.\n\n   1. Patients with untreated brain metastases ≤ 30 mm that are asymptomatic, do not have significant edema, and do not require steroids or anti-seizure medications are eligible after discussion with the Medical Monitor.\n   2. Patients with previously treated brain metastases may participate provided they are stable after treatment and without evidence of progression by imaging for at least 4 weeks prior to the first dose of IP administration and are not using corticosteroids for at least 7 days prior to IP administration.\n   3. Patients with confirmed leptomeningeal disease are to be excluded.\n4. Unresolved toxicity from prior antitumor therapy defined as AEs \\> Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, except for alopecia; neurotoxicity AEs of patients who have received prior chemotherapy needs to be restored to Grade 2 or below. Patients with ≥ Grade 3 bleeding within 4 weeks of first study treatment dose should be excluded.\n5. Taken a medication that is a strong cytochrome P450 (CYP3A) inhibitor or inducer within 14 days of initiation of study therapy dosing.\n6. Taken a known corrected QT (QTc) interval prolongating medication within 7 days of initiation or longer if the half-life of the QTc prolonging medication is such that the drug is not cleared from the body within 7 days (5 half-lives) of initiation of study therapy dosing.\n7. Active dysphagia, digestive system disease, malabsorption syndrome, or other conditions affecting PAS-004 absorption.\n8. Previous or current retinal vein stenosis, retinal detachment, central retinal vein occlusion, or currently active glaucoma.\n9. Active interstitial pneumonia, including clinically significant radiation pneumonitis.\n10. Impaired cardiac function or cardiac disease as indicated by:\n\n    1. Average QTc interval \\> 470 ms as calculated according to the QTc formula of the instrument at the research center where electrocardiogram (ECG) measurements are performed.\n    2. Grade ≥ 3 congestive heart failure per New York Heart Association (NYHA) guidelines.\n    3. Clinically significant arrhythmias, including but not limited to, complete left bundle branch conduction abnormalities and 2nd degree atrioventricular block.\n11. Pregnant or lactating female patients.\n12. Known allergy or hypersensitivity to the investigational product (IP), including excipients, or history of severe adverse reaction to any drug, or sensitivity to components of the IP.\n13. Clinically active bacterial, fungal, or viral infections, hepatitis B (hepatitis B virus surface antigen positive and hepatitis B virus DNA over 1000 IU\u002Fml) or hepatitis C (hepatitis C virus RNA positive), human immunodeficiency virus infection (HIV positive).",{"count":119,"type":20},48,[87],"The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are:\n\n* How well participants are able tolerate different doses of PAS-004, and\n* What side effects PAS-004 might have.\n\nStudy participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety. Everyone participating in the study will take PAS-004 by mouth as a single dose, followed by one week observation, then once a day during the study, in 28-day cycles. Participants will continue on daily PAS-004 for up to 2 years, or until:\n\n* They decide to withdraw from the study, or\n* They experience unacceptable side effects, or\n* Their disease progresses, or another illness interferes with taking the study drug, or\n* The sponsors stops the study.",[123,43,124,125],"RAS Mutation","RAF Mutation","Advanced Solid Tumors",[127,128,125,129],"Cancer","malignant neoplasms","MAP Kinase Signaling Pathway","2025-11-25",{"date":132,"type":67},"2025-12-03",{"date":134,"type":67},"2024-02-29",{"date":136,"type":20},"2027-02",{"name":108,"class":109},7]